ARTICLE | Distillery Therapeutics
Cancer
November 15, 2017 7:22 PM UTC
Mouse studies suggest extracellular matrix (ECM)-binding mAbs against PD-L1 and CTLA-4 could help treat melanoma and breast cancer without adverse side effects. The anti-PD-L1 and anti-CLTA-4 mAbs wer...
BCIQ Company Profiles